Novanta Inc.
Every calculator, already run for NOVT
Open the full toolkit →You have the numbers on NOVT. Get the argument.
A written report on which of these readings actually decide the outcome for Novanta Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
3 analysts covering NOVTAnalyst Price Target Disagreement for Novanta Inc.
Wall Street's bull case implies +33% from the current price; the bear case implies +32%. Analysts are relatively aligned on NOVT's range.
Ownership & short interest
Insider Trading Activity for NOVT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical las…
NOVT — frequently asked
Is NOVT a buy right now?
Wall Street's consensus rating on Novanta Inc. is none across 3 analysts, with a mean price target of $194.50 (+33% vs. the current $146.56). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is NOVT overvalued?
NOVT trades at 92.8x trailing earnings, against a DCF fair value of $42 per share. The current price implies 24% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is NOVT's next earnings date?
Novanta Inc. is next scheduled to report earnings around Nov 3, 2026. A full NOVT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Novanta Inc.?
Analysts covering Novanta Inc. (NOVT) range from a bear-case target of $194.00 to a bull-case high of $195.00, with a mean consensus target of $194.50 across 2 analysts. The spread of $1.00 (1% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Novanta Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Novanta Inc.
Start with the evergreen guides that matter most for Technology, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NOVT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Novanta Inc., in minutes. 3 free reports included with every account — no credit card required.